MedPath

Enhanced Recovery After Surgery (ERAS) in Gynecological Surgery (ERASGS-01)

Not Applicable
Completed
Conditions
Gynecologic Disease
Gynecologic Cancer
Interventions
Procedure: ERAS protocol
Registration Number
NCT03629626
Lead Sponsor
Shandong University
Brief Summary

Enhanced recovery programs are composed of preoperative, intraoperative and postoperative strategies combined to form a multi-modal pathway. ERAS requires a multidisciplinary team of anesthetists, surgeons and nurses for successful implementation and realization of its advantages.The aim of this study is to compare outcomes of conventional perioperative care with those of an enhanced recovery after surgery (ERAS) perioperative care plan in women undergoing surgery for gynecologic cancer or suspected gynecologic disease.

Detailed Description

The study design is a two-arm, randomized, controlled trial. The control arm will consist of standard conventional perioperative care. The intervention arm will consist of a protocol-driven ERAS program. The investigators believe that this information will be very useful because although there is a national interest in creating ERAS protocols for gynecology, there currently is very little published on the subject. Investigators hypothesize that those patients randomized to the ERAS protocol will have shorter lengths of hospital stay and complications, without increasing readmission rates. The investigators would like to publish the investigators' results and protocol as a resource for other institutions to adopt.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
540
Inclusion Criteria
  • Age >18 and <70 years old
  • Patients candidated for elective gynecological surgery for benign pathology
  • Patients with diagnosis of gynecological neoplasm and candidated for elective gynecological surgery
  • Signed consent form
Exclusion Criteria
  • Contraindication to loco-regional anaesthesia
  • Patients with ileus or subocclusive condition prior surgery
  • Coagulation disorders
  • Organ failure or severe disfunction (heart, renal, pulmonary, hepatic)
  • Uncontrolled hypertension (>180/95)
  • Alcohol or drug abuser (current or previous)
  • Psychiatric condition or language barriers
  • Planned Intensive Care Recovery

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ERAS protocolERAS protocolpreoperative / intraoperative/ postoperative management
Primary Outcome Measures
NameTimeMethod
Shorter Length Of Hospitalization (LOH)Up to 4 weeks after surgery

Total amount of days spent in hospital

Secondary Outcome Measures
NameTimeMethod
Presence/Absence of nauseaAt moment 0, 3, 6, 12 and 24 hours after surgery

Treatment for postoperative nausea

Readmission ratesUp to 21 days post surgery

Readmissions to the hospital

Time to flatusUp to 4 weeks after surgery

Hours elapsed to event

Presence/Absence of vomitingAt moment 0, 3, 6, 12 and 24 hours after surgery

Treatment for postoperative vomiting

Foley catheter removalFrom 1 to 14days post surgery

Time to Foley catheter removal postoperative

Time to drinkUp to 4 weeks after surgery

Hours elapsed to event

Time to eatingUp to 4 weeks after surgery

Hours elapsed to event

Time to bowel movementUp to 4 weeks after surgery

Hours elapsed to event

Time to walkingUp to 4 weeks after surgery

Hours elapsed to event

Postoperative complicationsUp to 2 weeks after surgery

Rate measurement

Assessment of postoperative painAt moment 24 hours after surgery

Measurement of pain score post-operation will be obtained using clinical data gathered by the care team providing routine clinical care, and asking routine pain score questions. The scale used is the standard 1-10 pain scale, with 1 being no pain or very mild discomfort, and 10 being very severe pain.

Time to adjuvant treatment60 days

Time participant receives adjuvant treatment, if needed (chemotherapy or radiation)

Trial Locations

Locations (1)

Qilu Hospital of Shandong University

🇨🇳

Jinan, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath